1-(2-hydroxyphenyl)-2-(2H-tetrazol-5-yl)ethanone is a chemical compound with the molecular formula C9H8N4O2. It is also known as **(2-Hydroxyphenyl)acetyltetrazole** or **(2-Hydroxybenzoyl)tetrazole**.
This compound is important for research due to its potential applications in various fields, including:
**1. Pharmaceutical Research:**
* **Anti-inflammatory Activity:** Studies have shown that (2-Hydroxyphenyl)acetyltetrazole exhibits significant anti-inflammatory activity, potentially acting as a COX-2 inhibitor. This makes it a promising candidate for the development of new anti-inflammatory drugs.
* **Anti-cancer Activity:** Some research suggests that the compound has anti-cancer properties, particularly against certain types of leukemia cells. This warrants further investigation to explore its therapeutic potential.
* **Neuroprotective Activity:** Studies suggest that (2-Hydroxyphenyl)acetyltetrazole might protect neurons from damage caused by oxidative stress, making it relevant for research on neurodegenerative diseases like Alzheimer's and Parkinson's.
**2. Material Science:**
* **Coordination Chemistry:** The tetrazole ring in the molecule can act as a ligand, forming coordination complexes with various metals. This property makes the compound useful in developing new materials with potential applications in catalysis, sensing, and bioimaging.
**3. Organic Synthesis:**
* **Building Block:** Due to its structure and functional groups, (2-Hydroxyphenyl)acetyltetrazole can serve as a valuable building block in organic synthesis, enabling the creation of novel and complex molecules with various potential uses.
**Current Research:**
While (2-Hydroxyphenyl)acetyltetrazole has shown promise in various areas, research is ongoing to:
* **Further elucidate its mechanism of action:** Understanding how the compound interacts with biological systems is crucial for optimizing its therapeutic applications.
* **Develop more potent and selective derivatives:** Researchers are exploring modifications to the molecule to improve its efficacy and target specific biological pathways.
* **Investigate its safety and pharmacokinetic properties:** Before any clinical trials can be conducted, researchers need to establish the safety and effectiveness of the compound in living organisms.
Overall, 1-(2-hydroxyphenyl)-2-(2H-tetrazol-5-yl)ethanone is a fascinating molecule with the potential to revolutionize various fields. Further research is crucial to unlock its full potential and develop safe and effective applications.
ID Source | ID |
---|---|
PubMed CID | 902451 |
CHEMBL ID | 1327686 |
CHEBI ID | 107399 |
Synonym |
---|
smr000231107 |
MLS000704799 |
1-(2-hydroxyphenyl)-2-(1h-tetraazol-5-yl)ethanone |
CHEBI:107399 |
1-(2-hydroxyphenyl)-2-(2h-tetrazol-5-yl)ethanone |
HMS2562L20 |
60723-60-6 |
CHEMBL1327686 |
Q27185708 |
DTXSID40358572 |
1-(2-hydroxyphenyl)-2-(1h-1,2,3,4-tetrazol-5-yl)ethan-1-one |
EN300-6733138 |
Z1513821069 |
Class | Description |
---|---|
aromatic ketone | A ketone in which the carbonyl group is attached to an aromatic ring. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 28.1838 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 5.0000 | 0.1409 | 11.1940 | 39.8107 | AID2451 |
Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 44.6684 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
huntingtin isoform 2 | Homo sapiens (human) | Potency | 5.6234 | 0.0006 | 18.4198 | 1,122.0200 | AID1688 |
geminin | Homo sapiens (human) | Potency | 1.2995 | 0.0046 | 11.3741 | 33.4983 | AID624297 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1145602 | Antiallergic activity in iv dosed Sprague-Dawley rat assessed as inhibition of egg albumin-induced passive cutaneous anaphylaxis administered immediately prior to egg albumin challenge measured after 30 mins by Evan blue dye leakage assay relative to diso | 1977 | Journal of medicinal chemistry, Jan, Volume: 20, Issue:1 | Studies on antianaphylactic agents. 5. Synthesis of 3-(1H-tetrazol-5-yl)chromones, a new series of antiallergic substances. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (16.67) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (16.67) | 29.6817 |
2010's | 3 (50.00) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.19) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |